Please use this identifier to cite or link to this item:
|Title:||Tumour necrosis factors in clinical practice|
|Source:||Goh, C.R. (1990). Tumour necrosis factors in clinical practice. Annals of the Academy of Medicine Singapore 19 (2) : 235-239. ScholarBank@NUS Repository.|
|Abstract:||The tumour necrosis factors are pleiotropic proteins which have a wide range of biological activities. Tumour necrosis factor-α or cachectin is a product of macrophages and is the principal host mediator of septic shock and the cachexia of chronic disease. A related molecule, tumour necrosis factor-β or lymphotoxin, is produced by T lymphocytes in response to antigen or mitogens. The role of the TNFs in disease processes and in therapy are reviewed. Both agents exert antiproliferative effects on certain tumour cell lines, while normal cells are resistant to these effects. In vivo, they cause haemorrhagic necrosis of certain implantable tumors in mice. Trials of tumour necrosis factor-α as an anticancer agent, either singly or in combination with interferon gamma or cytotoxic drugs, are in progress. Understanding the involvement of the tumour necrosis factors in pathological processes may lead to new therapies for endotoxic shock and cancer.|
|Source Title:||Annals of the Academy of Medicine Singapore|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 20, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.